Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more
Cytokinetics (CYTK) has spent recent weeks consolidating within a relatively narrow band, with its latest close near $63.95 compared with roughly $67.56 about 30 days prior — a decline of approximately 5%. The move has been incremental rather than driven by a single event, consistent with the stock trading near the lower end of its recent range. Broader sentiment toward commercial-stage biotech names has been cautious, even for companies reporting encouraging launch metrics, which has contributed to modest downward drift in the share price.
Cytokinetics is a specialty cardiovascular biopharmaceutical company based in South San Francisco, California, with more than two decades of expertise in muscle biology. The company discovers and develops small molecules that modulate cardiac muscle contractility, targeting diseases of cardiac muscle dysfunction.
Its lead asset, MYQORZO (aficamten), is an allosteric and reversible cardiac myosin inhibitor designed to reduce cardiac contractility and left ventricular outflow tract obstruction in patients with oHCM. Following FDA approval in December 2025, the company has executed a staged global commercialization strategy, with launches in the U.S. and Europe (beginning in Germany) during 2026. The pipeline also includes omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction, positioning Cytokinetics as a leader in cardiac myosin biology.
Several verified developments have shaped investor sentiment over the last 30 days. On October 19, 2026, the company announced Health Canada approval of MYQORZO for adults with symptomatic oHCM — its fifth regulatory approval in under a year, following clearances in the U.S., China, the European Union, and the United Kingdom. This milestone reinforces the drug's expanding global footprint.
On the clinical front, full results from ACACIA-HCM, the pivotal Phase 3 trial of aficamten in non-obstructive HCM, were presented at the ESC Congress 2026 and published in The New England Journal of Medicine. The trial met both dual primary endpoints, showing statistically significant improvements in patient-reported and physician-assessed measures, and supports a potential label expansion into nHCM.
Analyst activity has remained constructive. RBC Capital raised its price target to $113 while maintaining an Outperform rating, H.C. Wainwright reiterated a Buy rating with a $140 target, and Needham maintained a Buy rating with a $112 target. Despite these positive signals, shares have lagged, partly reflecting caution ahead of the MAPLE-HCM supplemental new drug application (sNDA) decision and general risk-off positioning in biotech.
Tickeron's Trending AI Robots page curates a selection of automated trading systems drawn from a much larger universe of AI-driven bots that monitor thousands of tickers. Only the top-performing and most relevant robots appear in this featured section, giving traders a focused view of strategies that are currently demonstrating notable results. Each robot varies in trading strategy, holding timeframe, and performance metrics, so the page offers a convenient way to compare different approaches side by side. Traders interested in data-driven market analysis can explore the section to see which AI strategies are generating momentum.
Investors are likely to focus on several catalysts through the remainder of 2026. The FDA has assigned a target action date of November 14, 2026 for the MAPLE-HCM sNDA, which seeks to expand aficamten's label based on its superiority over metoprolol as monotherapy. A favorable decision could broaden the addressable market and reinforce the drug's competitive differentiation.
Commercial execution remains central, with attention on U.S. prescription trends, European launch progress, and future market access in Canada and other regions. Continued data readouts across the pipeline, including ACACIA-HCM follow-up analyses and the ongoing CEDAR-HCM pediatric study, could further shape sentiment. Broader macroeconomic conditions, biotech sector risk appetite, and financing dynamics also remain relevant variables. As a company transitioning from clinical-stage to commercial-stage, Cytokinetics' ability to sustain revenue growth while managing operating expenses will be closely monitored.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for CYTK entered a downward trend on November 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 173 similar instances where the Aroon Indicator formed such a pattern. In 152 of the 173 cases the stock moved lower. This puts the odds of a downward move at 88%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 78 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 44 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 212 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CYTK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-43.024) is normal, around the industry mean (3.596). P/E Ratio (-7.436) is within average values for comparable stocks, (-1.186). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which engages in discovery and development of small molecule drug therapeutics
Industry Biotechnology